MX341958B - Anticuerpos contra el il33r humano y usos de los mismos. - Google Patents

Anticuerpos contra el il33r humano y usos de los mismos.

Info

Publication number
MX341958B
MX341958B MX2013009442A MX2013009442A MX341958B MX 341958 B MX341958 B MX 341958B MX 2013009442 A MX2013009442 A MX 2013009442A MX 2013009442 A MX2013009442 A MX 2013009442A MX 341958 B MX341958 B MX 341958B
Authority
MX
Mexico
Prior art keywords
seq
region
antibodies against
against human
il33r
Prior art date
Application number
MX2013009442A
Other languages
English (en)
Other versions
MX2013009442A (es
Inventor
Fertig Georg
Georges Guy
Kaluza Klaus
Lifke Valeria
Moelleken Joerg
Offner Sonja
Pashine Achal
Seeber Stefan
Fischer Jens
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013009442A publication Critical patent/MX2013009442A/es
Publication of MX341958B publication Critical patent/MX341958B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo que se une al IL33R caracterizado porque el dominio variable de cadena pesada contiene una región CDR3 de SEC ID NO: 1, una región CDR2 de SEC ID NO: 2 y una región CDR1 de SEC ID NO: 3 y porque el dominio variable de cadena ligera contiene una región CDR3 de SEC ID NO: 4, una región CDR2 de SEC ID NO: 5 y una región CDR1 de SEC ID NO: 6 o una variante del mismo anticuerpo quimérica, humanizada o desprovista del epítopo de células T, que tiene propiedades ventajosas para el tratamiento de enfermedades inflamatorias.
MX2013009442A 2011-02-23 2012-02-22 Anticuerpos contra el il33r humano y usos de los mismos. MX341958B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11155684 2011-02-23
PCT/EP2012/052979 WO2012113813A1 (en) 2011-02-23 2012-02-22 Antibodies against human il33r and uses thereof

Publications (2)

Publication Number Publication Date
MX2013009442A MX2013009442A (es) 2013-10-01
MX341958B true MX341958B (es) 2016-09-08

Family

ID=45688517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009442A MX341958B (es) 2011-02-23 2012-02-22 Anticuerpos contra el il33r humano y usos de los mismos.

Country Status (13)

Country Link
US (2) US8785153B2 (es)
EP (1) EP2678358B1 (es)
JP (1) JP6147674B2 (es)
KR (1) KR102003075B1 (es)
CN (1) CN103562224B (es)
AR (1) AR085383A1 (es)
BR (1) BR112013021473A2 (es)
CA (1) CA2824500C (es)
ES (1) ES2549637T3 (es)
MX (1) MX341958B (es)
RU (1) RU2597288C2 (es)
TW (1) TW201238976A (es)
WO (1) WO2012113813A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
AU2013285355A1 (en) * 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
HUE048722T2 (hu) * 2013-07-05 2020-08-28 Genmab As Humanizált vagy kiméra CD3 ellenanyagok
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
EA039540B1 (ru) * 2016-03-25 2022-02-08 Онкомед Фармасьютикалс, Инк. Связывающие tigit агенты и варианты их применения
PE20181952A1 (es) 2016-04-27 2018-12-17 Pfizer Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
CN108299557A (zh) * 2017-01-13 2018-07-20 杭州翰思生物医药有限公司 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
IL307286B1 (en) 2018-04-11 2025-11-01 Regeneron Pharma Methods and compositions for quantifying il-33
CN111434687B (zh) * 2019-01-15 2022-03-11 南京赛新生物科技有限公司 一种抗体及其应用
CN111434680B (zh) * 2019-01-15 2021-11-23 南京赛新生物科技有限公司 一种与il33相关疾病的抗原表位肽及其应用
CN112480254B (zh) * 2019-09-12 2023-06-06 上海麦济生物技术有限公司 抗人白细胞介素-33受体的抗体及其制备方法和应用
CN113214395A (zh) * 2020-01-21 2021-08-06 迈威(上海)生物科技股份有限公司 抗st2抗体及其应用
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN117624356B (zh) * 2024-01-26 2024-04-12 南京诺唯赞医疗科技有限公司 NfL特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB9727172D0 (en) * 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CN1942483B (zh) * 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TW200720289A (en) * 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
WO2007130627A2 (en) * 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders

Also Published As

Publication number Publication date
ES2549637T3 (es) 2015-10-30
CA2824500C (en) 2020-02-25
US20120213774A1 (en) 2012-08-23
KR20140020923A (ko) 2014-02-19
MX2013009442A (es) 2013-10-01
RU2597288C2 (ru) 2016-09-10
RU2013140350A (ru) 2015-03-27
WO2012113813A1 (en) 2012-08-30
BR112013021473A2 (pt) 2020-08-04
EP2678358A1 (en) 2014-01-01
CA2824500A1 (en) 2012-08-30
EP2678358B1 (en) 2015-07-22
US8785153B2 (en) 2014-07-22
US9309319B2 (en) 2016-04-12
US20140302015A1 (en) 2014-10-09
TW201238976A (en) 2012-10-01
JP6147674B2 (ja) 2017-06-14
KR102003075B1 (ko) 2019-07-23
AR085383A1 (es) 2013-09-25
CN103562224A (zh) 2014-02-05
CN103562224B (zh) 2017-08-22
JP2014508520A (ja) 2014-04-10

Similar Documents

Publication Publication Date Title
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ712765A (en) Antibodies that bind csf1r
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
NZ602020A (en) Anti-cd40 antibodies
NZ724971A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ616382A (en) Antibodies specific to cadherin-17
NZ605980A (en) Anti-fap antibodies and methods of use
TN2014000107A1 (en) Anti-aplhabetatcr antibody
AR082163A1 (es) Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
NZ626269A (en) Anti-phf-tau antibodies and their uses
NZ600005A (en) Antibodies against human angiopoietin 2
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ715896A (en) Humanized or chimeric cd3 antibodies
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
NZ595235A (en) Compositions and methods for increasing muscle growth
WO2011139974A3 (en) Anti-pai-1 antibodies and methods of use thereof
WO2012109280A3 (en) Apoe immunotherapy
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
NZ603182A (en) Humanized anti cxcr4 antibodies for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration